Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, loxapine (Adasuve®) cannot be endorsed for use within NHS Wales for rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. |
||
|
||
Medicine details |
||
| Medicine name | loxapine (Adasuve®) | |
| Formulation | 4.5 mg and 9.1 mg inhalation powder | |
| Reference number | 1143 | |
| Indication | Rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder |
|
| Company | Alexza UK Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/07/2013 | |